Evaluation of cannabinoids concentration and stability in standardized preparations of cannabis tea and cannabis oil by ultra-high performance liquid chromatography tandem mass spectrometry

Abstract Background: Cannabis has been used since ancient times to relieve neuropathic pain, to lower intraocular pressure, to increase appetite and finally to decrease nausea and vomiting. The combination of the psychoactive cannabis alkaloid Δ9-tetrahydrocannabinol (THC) with the non-psychotropic alkaloids cannabidiol (CBD) and cannabinol (CBN) demonstrated a higher activity than THC alone. The Italian National Institute of Health sought to establish conditions and indications on how to correctly use nationally produced cannabis to guarantee therapeutic continuity in individuals treated with medical cannabis. Methods: The evaluation of cannabinoids concentration and stability in standardized preparations of cannabis tea and cannabis oil was conducted using an easy and fast ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) assay. Results: Extraction efficiency of oil was significantly higher than that of water with respect to the different cannabinoids. This was especially observed in the case of the pharmacologically active THC, CBD and their acidic precursors. Fifteen minutes boiling was sufficient to achieve the highest concentrations of cannabinoids in the cannabis tea solutions. At ambient temperature, a significant THC and CBD decrease to 50% or less of the initial concentration was observed over 3 and 7 days, respectively. When refrigerated at 4 °C, similar decreasing profiles were observed for the two compounds. The cannabinoids profile in cannabis oil obtained after pre-heating the flowering tops at 145 °C for 30 min in a static oven resulted in a complete decarboxylation of cannabinoid acids CBDA and THCA-A. Nevertheless, it was apparent that heat not only decarboxylated acidic compounds, but also significantly increased the final concentrations of cannabinoids in oil. The stability of cannabinoids in oil samples was higher than that in tea samples since the maximum decrease (72% of initial concentration) was observed in THC coming from unheated flowering tops at ambient temperature. In the case of the other cannabinoids, at ambient and refrigerated temperatures, 80%–85% of the initial concentrations were measured up to 14 days after oil preparation. Conclusions: As the first and most important aim of the different cannabis preparations is to guarantee therapeutic continuity in treated individuals, a strictly standardized preparation protocol is necessary to assure the availability of a homogeneous product of defined stability.

[1]  T. Veress,et al.  Determination of cannabinoid acids by high-performance liquid chromatography of their neutral derivatives formed by thermal decarboxylation. I. Study of the decarboxylation process in open reactors , 1990 .

[2]  R. Mechoulam,et al.  Cannabinoids in health and disease , 2007, Dialogues in clinical neuroscience.

[3]  T. Järvinen,et al.  Cannabinoids in the treatment of glaucoma. , 2002, Pharmacology & therapeutics.

[4]  G. Guy,et al.  A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. , 2006, Medical hypotheses.

[5]  Giuseppe Cannazza,et al.  Medicinal cannabis: Principal cannabinoids concentration and their stability evaluated by a high performance liquid chromatography coupled to diode array and quadrupole time of flight mass spectrometry method. , 2016, Journal of pharmaceutical and biomedical analysis.

[6]  R. Torre,et al.  Stability of Drugs of Abuse in Oral Fluid Collection Devices With Purpose of External Quality Assessment Schemes , 2009, Therapeutic drug monitoring.

[7]  C. Limebeer,et al.  Effect of combined doses of Δ9-tetrahydrocannabinol (THC) and cannabidiolic acid (CBDA) on acute and anticipatory nausea using rat (Sprague- Dawley) models of conditioned gaping , 2015, Psychopharmacology.

[8]  M. Guzmán,et al.  Cannabis in cancer care , 2015, Clinical pharmacology and therapeutics.

[9]  Benjamin J. Whalley,et al.  Neuromotor tolerability and behavioural characterisation of cannabidiolic acid, a phytocannabinoid with therapeutic potential for anticipatory nausea , 2015, Psychopharmacology.

[10]  K. Verhoeckx,et al.  Unheated Cannabis sativa extracts and its major compound THC-acid have potential immuno-modulating properties not mediated by CB1 and CB2 receptor coupled pathways. , 2006, International immunopharmacology.

[11]  C. Limebeer,et al.  Tetrahydrocannabinolic acid reduces nausea‐induced conditioned gaping in rats and vomiting in Suncus murinus , 2013, British journal of pharmacology.

[12]  Arno Hazekamp,et al.  Cannabis Oil: chemical evaluation of an upcoming cannabis-based medicine , 2013 .

[13]  P. C. Karlsson,et al.  Evaluation of the cyclooxygenase inhibiting effects of six major cannabinoids isolated from Cannabis sativa. , 2011, Biological & pharmaceutical bulletin.

[14]  Penny F Whiting,et al.  Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. , 2015, JAMA.

[15]  J. McPartland,et al.  Cannabis is more than simply Δ9-tetrahydrocannabinol , 2003, Psychopharmacology.

[16]  R. Mechoulam,et al.  Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease , 2005, Neurobiology of Disease.

[17]  K. Müller-Vahl,et al.  Cannabinoids reduce symptoms of Tourette’s syndrome , 2003, Expert opinion on pharmacotherapy.

[18]  M. Cascio,et al.  Cannabidiolic acid prevents vomiting in Suncus murinus and nausea‐induced behaviour in rats by enhancing 5‐HT1A receptor activation , 2013, British journal of pharmacology.

[19]  R. Pacula,et al.  In the weeds: a baseline view of cannabis use among legalizing states and their neighbours. , 2016, Addiction.

[20]  W. Rausch,et al.  Effects of cannabinoids Δ(9)-tetrahydrocannabinol, Δ(9)-tetrahydrocannabinolic acid and cannabidiol in MPP+ affected murine mesencephalic cultures. , 2012, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[21]  Arno Hazekamp,et al.  Cannabis tea revisited: a systematic evaluation of the cannabinoid composition of cannabis tea. , 2007, Journal of ethnopharmacology.

[22]  H. Aramaki,et al.  Down-regulation of cyclooxygenase-2 (COX-2) by cannabidiolic acid in human breast cancer cells. , 2014, The Journal of toxicological sciences.

[23]  A. Christophersen Tetrahydrocannabinol stability in whole blood: plastic versus glass containers. , 1986, Journal of analytical toxicology.